Selected research
Industry Growth & Trends
Global Untargeted Metabolomics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Untargeted Metabolomics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Untargeted Metabolomics market include Creative Proteomics, Metabolon, Alfa Chemistry, Novelgene Technologies, MtoZ-Biolabs Inc., CD Genomics, Metware Biotechnology Inc (Metware), BGI Genomics and APPLIED PROTEIN TECHNOLOGY, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Untargeted Metabolomics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Untargeted Metabolomics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Untargeted Metabolomics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Untargeted Metabolomics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Untargeted Metabolomics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Untargeted Metabolomics Market by Company
Creative Proteomics
Metabolon
Alfa Chemistry
Novelgene Technologies
MtoZ-Biolabs Inc.
CD Genomics
Metware Biotechnology Inc (Metware)
BGI Genomics
APPLIED PROTEIN TECHNOLOGY
Suzhou PANOMIX Biomedical Tech Co.,Ltd
OBiO Technology ( Shanghai ) Corp.,Ltd.
Beijing Huayi innovation & BioTechnology Co., Ltd
Abace Biotechnology
Metabo-Profile
Untargeted Metabolomics Segment by Type
Plant Untargeted Metabolomics
Human Untargeted Metabolomics
Other
Untargeted Metabolomics Segment by Application
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Untargeted Metabolomics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Untargeted Metabolomics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Untargeted Metabolomics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Untargeted Metabolomics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Untargeted Metabolomics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Plant Untargeted Metabolomics
- Human Untargeted Metabolomics
- Other
Applications
- Academic and Research Institutions
- Pharmaceutical and Biotechnology Companies
Companies covered
- Creative Proteomics
- Metabolon
- Alfa Chemistry
- Novelgene Technologies
- MtoZ-Biolabs Inc.
- CD Genomics
- Metware Biotechnology Inc (Metware)
- BGI Genomics
- APPLIED PROTEIN TECHNOLOGY
- Suzhou PANOMIX Biomedical Tech Co.,Ltd
- OBiO Technology ( Shanghai ) Corp.,Ltd.
- Beijing Huayi innovation & BioTechnology Co., Ltd
- Abace Biotechnology
- Metabo-Profile
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Untargeted Metabolomics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Untargeted Metabolomics Market Size by Region (2021-2032)
- 1.4.1 Global Untargeted Metabolomics Market Size by Region (2021-2026)
- 1.4.2 Global Untargeted Metabolomics Market Size by Region (2027-2032)
- 1.5 Key Regions Untargeted Metabolomics Market Size (2021-2032)
- 1.5.1 North America Untargeted Metabolomics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Untargeted Metabolomics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Untargeted Metabolomics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Untargeted Metabolomics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Untargeted Metabolomics Market Size Growth Rate (2021-2032)
2 Untargeted Metabolomics Market by Type
- 2.1 Type Introduction
- 2.1.1 Plant Untargeted Metabolomics
- 2.1.2 Human Untargeted Metabolomics
- 2.1.3 Other
- 2.2 Global Untargeted Metabolomics Market Size by Type
- 2.2.1 Global Untargeted Metabolomics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Untargeted Metabolomics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Untargeted Metabolomics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Untargeted Metabolomics Market Size by Regions
- 2.3.1 North America Untargeted Metabolomics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Untargeted Metabolomics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Untargeted Metabolomics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Untargeted Metabolomics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Untargeted Metabolomics Market Size Breakdown by Type (2021-2026)
3 Untargeted Metabolomics Market by Application
- 3.1 Type Introduction
- 3.1.1 Academic and Research Institutions
- 3.1.2 Pharmaceutical and Biotechnology Companies
- 3.2 Global Untargeted Metabolomics Market Size by Application
- 3.2.1 Global Untargeted Metabolomics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Untargeted Metabolomics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Untargeted Metabolomics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Untargeted Metabolomics Market Size by Regions
- 3.3.1 North America Untargeted Metabolomics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Untargeted Metabolomics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Untargeted Metabolomics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Untargeted Metabolomics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Untargeted Metabolomics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Untargeted Metabolomics Industry Trends
- 4.2 Untargeted Metabolomics Industry Drivers
- 4.3 Untargeted Metabolomics Industry Opportunities and Challenges
- 4.4 Untargeted Metabolomics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Untargeted Metabolomics Revenue (2021-2026)
- 5.2 Global Untargeted Metabolomics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Untargeted Metabolomics Key Company Headquarters & Area Served
- 5.4 Global Untargeted Metabolomics Company, Product Type & Application
- 5.5 Global Untargeted Metabolomics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Untargeted Metabolomics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Untargeted Metabolomics Players Market Share by Revenue in 2025
- 5.6.3 2025 Untargeted Metabolomics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Creative Proteomics
- 6.1.1 Creative Proteomics Company Information
- 6.1.2 Creative Proteomics Business Overview
- 6.1.3 Creative Proteomics Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Creative Proteomics Untargeted Metabolomics Product Portfolio
- 6.1.5 Creative Proteomics Recent Developments
- 6.2 Metabolon
- 6.2.1 Metabolon Company Information
- 6.2.2 Metabolon Business Overview
- 6.2.3 Metabolon Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Metabolon Untargeted Metabolomics Product Portfolio
- 6.2.5 Metabolon Recent Developments
- 6.3 Alfa Chemistry
- 6.3.1 Alfa Chemistry Company Information
- 6.3.2 Alfa Chemistry Business Overview
- 6.3.3 Alfa Chemistry Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Alfa Chemistry Untargeted Metabolomics Product Portfolio
- 6.3.5 Alfa Chemistry Recent Developments
- 6.4 Novelgene Technologies
- 6.4.1 Novelgene Technologies Company Information
- 6.4.2 Novelgene Technologies Business Overview
- 6.4.3 Novelgene Technologies Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novelgene Technologies Untargeted Metabolomics Product Portfolio
- 6.4.5 Novelgene Technologies Recent Developments
- 6.5 MtoZ-Biolabs Inc.
- 6.5.1 MtoZ-Biolabs Inc. Company Information
- 6.5.2 MtoZ-Biolabs Inc. Business Overview
- 6.5.3 MtoZ-Biolabs Inc. Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 MtoZ-Biolabs Inc. Untargeted Metabolomics Product Portfolio
- 6.5.5 MtoZ-Biolabs Inc. Recent Developments
- 6.6 CD Genomics
- 6.6.1 CD Genomics Company Information
- 6.6.2 CD Genomics Business Overview
- 6.6.3 CD Genomics Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 CD Genomics Untargeted Metabolomics Product Portfolio
- 6.6.5 CD Genomics Recent Developments
- 6.7 Metware Biotechnology Inc (Metware)
- 6.7.1 Metware Biotechnology Inc (Metware) Company Information
- 6.7.2 Metware Biotechnology Inc (Metware) Business Overview
- 6.7.3 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Product Portfolio
- 6.7.5 Metware Biotechnology Inc (Metware) Recent Developments
- 6.8 BGI Genomics
- 6.8.1 BGI Genomics Company Information
- 6.8.2 BGI Genomics Business Overview
- 6.8.3 BGI Genomics Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 BGI Genomics Untargeted Metabolomics Product Portfolio
- 6.8.5 BGI Genomics Recent Developments
- 6.9 APPLIED PROTEIN TECHNOLOGY
- 6.9.1 APPLIED PROTEIN TECHNOLOGY Company Information
- 6.9.2 APPLIED PROTEIN TECHNOLOGY Business Overview
- 6.9.3 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Product Portfolio
- 6.9.5 APPLIED PROTEIN TECHNOLOGY Recent Developments
- 6.10 Suzhou PANOMIX Biomedical Tech Co.,Ltd
- 6.10.1 Suzhou PANOMIX Biomedical Tech Co.,Ltd Company Information
- 6.10.2 Suzhou PANOMIX Biomedical Tech Co.,Ltd Business Overview
- 6.10.3 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Product Portfolio
- 6.10.5 Suzhou PANOMIX Biomedical Tech Co.,Ltd Recent Developments
- 6.11 OBiO Technology ( Shanghai ) Corp.,Ltd.
- 6.11.1 OBiO Technology ( Shanghai ) Corp.,Ltd. Company Information
- 6.11.2 OBiO Technology ( Shanghai ) Corp.,Ltd. Business Overview
- 6.11.3 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Product Portfolio
- 6.11.5 OBiO Technology ( Shanghai ) Corp.,Ltd. Recent Developments
- 6.12 Beijing Huayi innovation & BioTechnology Co., Ltd
- 6.12.1 Beijing Huayi innovation & BioTechnology Co., Ltd Company Information
- 6.12.2 Beijing Huayi innovation & BioTechnology Co., Ltd Business Overview
- 6.12.3 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Product Portfolio
- 6.12.5 Beijing Huayi innovation & BioTechnology Co., Ltd Recent Developments
- 6.13 Abace Biotechnology
- 6.13.1 Abace Biotechnology Company Information
- 6.13.2 Abace Biotechnology Business Overview
- 6.13.3 Abace Biotechnology Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Abace Biotechnology Untargeted Metabolomics Product Portfolio
- 6.13.5 Abace Biotechnology Recent Developments
- 6.14 Metabo-Profile
- 6.14.1 Metabo-Profile Company Information
- 6.14.2 Metabo-Profile Business Overview
- 6.14.3 Metabo-Profile Untargeted Metabolomics Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Metabo-Profile Untargeted Metabolomics Product Portfolio
- 6.14.5 Metabo-Profile Recent Developments
7 North America
- 7.1 North America Untargeted Metabolomics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Untargeted Metabolomics Market Size by Country (2021-2026)
- 7.3 North America Untargeted Metabolomics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Untargeted Metabolomics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Untargeted Metabolomics Market Size by Country (2021-2026)
- 8.3 Europe Untargeted Metabolomics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Untargeted Metabolomics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Untargeted Metabolomics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Untargeted Metabolomics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Untargeted Metabolomics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Untargeted Metabolomics Market Size by Country (2021-2026)
- 10.3 South America Untargeted Metabolomics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Untargeted Metabolomics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Untargeted Metabolomics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Untargeted Metabolomics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst